TY - JOUR T1 - Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.02490-2017 VL - 51 IS - 3 SP - 1702490 AU - Onno W. Akkerman AU - Floris Grasmeijer AU - Wiel C.M. de Lange AU - Huib A.M. Kerstjens AU - Gerard de Vries AU - Mathieu S. Bolhuis AU - Jan-Willem Alffenaar AU - Henderik W. Frijlink AU - Grace Smith AU - Roger Gajraj AU - Rina de Zwaan AU - Paul Hagedoorn AU - Martin Dedicoat AU - Dick van Soolingen AU - Tjip S. van der Werf Y1 - 2018/03/01 UR - http://erj.ersjournals.com/content/51/3/1702490.abstract N2 - Extensively drug-resistant (XDR) tuberculosis (TB) is defined by resistance to isoniazid, rifampicin, any fluoroquinolone and at least one of the three second line injectable drugs, such as amikacin. Drug toxicity and duration impair adherence to treatment and outcome is rather poor [1]. We report on a particularly challenging XDR-TB patient with persistent non-adherence to treatment and an exceptionally complex drug susceptibility pattern.Crossing borders by treating a patient with difficult to treat XDR-TB; highly individualised but holistic approach http://ow.ly/JyjK30ielsD ER -